Your AI-Trained Oncology Knowledge Connection!
We headed to Tampa, Florida for a State of the Science Summit on Hematologic Malignancies. The meeting covered updates in follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myeloproliferative neoplasms, and CAR T-cell therapy.
The Sidney Kimmel Cancer Center – Jefferson Health announces a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which launched today in the United States and China.
We traveled to Hanover, Maryland for a State of the Science SummitTM on Advanced Non–Small Cell Lung Cancer. The meeting covered the use of immunotherapy in metastatic and early-stage disease, management of immune-related toxicities, predictive biomarkers, and emerging therapies in small cell lung cancer.
Hackensack Meridian Health John Theurer Cancer Center at Hackensack University Medical Center will host its tenth annual Celebrating Life and Liberty event at MetLife Stadium September 14.
We traveled to Charlotte, North Carolina for a State of the Science Summit on Ovarian Cancer. The meeting covered genetic testing, frontline therapies, surgical options, treatment for recurrent disease, immunotherapy, and updates in uterine sarcomas.
A supplemental new drug application has been submitted to the FDA for a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.
The Association of Community Cancer Centers will honor the recipients of 2018 ACCC Innovator Awards at the ACCC 35th National Oncology Conference, October 17-19 in Phoenix, Arizona, where this year’s honorees will share strategies and lessons learned from their own experience to enable others to model and scale similar initiatives.
Combining Alpelisib (BYL719) with fulvestrant improved progression-free survival versus fulvestrant alone in postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutant advanced or metastatic breast cancer that progressed after aromatase inhibitor treatment with or without a CDK4/6 inhibitor, meeting the primary endpoint of the phase III SOLAR-1 trial.
This Dallas, Texas meeting on gastrointestinal (GI) cancers covered emerging therapies in pancreatic cancer, updates in neuroendocrine tumors, the management of metastatic colorectal cancer, recent data in hepatocellular carcinoma, and the clinical application of precision medicine in GI cancers.
Hackensack Meridian Health, New Jersey’s largest and most comprehensive healthcare network, is proud to announce the opening of the Institute for Multiple Myeloma which will support groundbreaking research to enhance treatment of this rare cancer.
We traveled to Charlottesville, Virginia for a State of the Science Summit on Advanced Non-Small Cell Lung Cancer. The conference spanned early-stage advances, established and emerging treatments for oncogenic-driven disease, chemotherapy, immunotherapy, and the role of radiation
The FDA has granted a priority review designation to a biologics license application for SL-401 (tagraxofusp, Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.
The National Heart, Lung and Blood Institute, part of the National Institutes of Health, awarded a $4.7 million grant to Cleveland Clinic to study the prevention of life-threatening, cancer-associated blood clots.
We went out to Denver, Colorado for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer. The conference spanned screening, molecular profiling, early-stage advances, treatment for oncogenic-driven advanced disease, and immunotherapy.
Conor E. Steuer, MD, shares insight on the emerging role of tumor mutational burden in relation to immunotherapy for patients with cancer.
Rinath M. Jeselsohn, MD, discusses the detection and clinical implications of ESR1 mutations.
Guadecitabine (SGI-110) did not meet the coprimary endpoints of the phase III ASTRAL-1 study comparing the hypomethylating agent with physician’s choice of standard therapy in treatment-naïve adult patients with AML.
There is an evolving role of gene mutations within the cancer treatment spectrum, from discoveries in tumor biology and detection technologies, to the development targeted therapies and the clinical impact of pivotal trial data.
Walker will lead patient care, nursing, ancillary and supportive service operations for the main Duarte campus and clinical network.
We traveled to Houston, Texas for a State of the Science Summit on Breast Cancer on July 11, 2018. The conference covered radiation therapy, triple-negative breast cancer, BRCA-positive tumors, takeaways from the 2018 ASCO Annual Meeting, and more.
The Association of Community Cancer Centers and Advisory Board's Oncology Roundtable are again conducting a comprehensive survey that will explore how cancer programs across the country are moving forward and adapting in the midst of exciting, increasingly rapid advances in cancer care coupled with unprecedented change underway across the U.S. healthcare system.
George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.
Paul Richardson, MD, discusses the efficacy and tolerability of the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone in patients with multiple myeloma.
We headed out to Kansas City, Missouri, for a State of the Science Summit on June 30, 2018, which spanned several tumor types and covered the highlights from the 2018 ASCO Annual Meeting.
Several studies presented at this year’s American Urological Association meeting underscored the value of multiparametric magnetic resonance imaging in the diagnosis and management of prostate cancer.
Patients with metastatic colorectal cancer who are not eligible for chemotherapy or surgical resection may have a new first-line treatment option.
TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.
The FDA has accepted a supplemental biologics license application for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.
Advanced sequencing techniques have revolutionized the understanding of how cancer has developed and enabled treatment selection based on genomic characterization of the tumor.